XML 101 R85.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenue $ 54,426,402 $ 53,376,874
Cost of Sales (50,115,079) (49,027,305)
General and administrative expenses (11,733,237) (19,642,005)
General and administrative expenses (7,038,805)  
Salaries (5,693,436) (4,554,909)
Sales and marketing expenses (354,969) (1,204,636)
Research and development costs (533,293)  
Net finance costs (605,865)  
Segment profit / (loss) (9,915,045)  
Depreciation and amortization (1,249,238) (614,377)
Provision (4,694,432)  
Impairment Charges (291,980) 0
Other income and expenses (32,323)  
Net profit/(loss) before Income Taxes (16,183,018) $ (18,542,654)
Other [Member]    
Revenue 0  
Cost of Sales 0  
General and administrative expenses (4,176,049)  
Salaries (1,317,580)  
Sales and marketing expenses (88,405)  
Research and development costs (533,293)  
Net finance costs (265)  
Segment profit / (loss) (6,115,592)  
Depreciation and amortization (118,448)  
Provision 0  
Impairment Charges (131,032)  
Other income and expenses 40,718  
Net profit/(loss) before Income Taxes (6,324,354)  
Wholesale [Member]    
Revenue 51,593,787  
Cost of Sales (48,887,569)  
General and administrative expenses (647,225)  
Salaries (1,701,552)  
Sales and marketing expenses (10,516)  
Research and development costs 0  
Net finance costs (840,456)  
Segment profit / (loss) (493,531)  
Depreciation and amortization (231,344)  
Provision (1,021,818)  
Impairment Charges 0  
Other income and expenses (304,495)  
Net profit/(loss) before Income Taxes (2,051,188)  
Pharma manufacturing [Member]    
Revenue 865,373  
Cost of Sales (249,061)  
General and administrative expenses (773,429)  
Salaries (1,243,568)  
Sales and marketing expenses (489)  
Research and development costs 0  
Net finance costs 0  
Segment profit / (loss) (1,401,174)  
Depreciation and amortization (565,371)  
Provision (123,503)  
Impairment Charges 0  
Other income and expenses 5,789  
Net profit/(loss) before Income Taxes (2,084,259)  
Nutraceuticals and Pharmaceuticals [Member]    
Revenue 1,967,242  
Cost of Sales (978,449)  
General and administrative expenses (1,442,102)  
Salaries (1,430,736)  
Sales and marketing expenses (255,559)  
Research and development costs 0  
Net finance costs (234,856)  
Segment profit / (loss) (1,904,748)  
Depreciation and amortization (334,075)  
Provision (3,549,111)  
Impairment Charges (160,948)  
Other income and expenses 225,665  
Net profit/(loss) before Income Taxes $ (5,723,217)